Rigel has executed numerous partnerships with small and large pharmaceutical companies over its history and we strive to be a partner of choice.
Our strategic transactions to date include in-licensing, out-licensing and product acquisitions of early-stage, late-stage and commercial assets.
Along with our commercial business, we continue to explore opportunities to create value through strategic collaborations with pharmaceutical and biotechnology companies that align with our commitment to bringing new therapies to patients with unmet medical needs.
Note: Rigel also has partnerships with BerGenBio (bemcentinib) and Daiichi Sankyo (milademetan)